UiPath Beheer
Beheer criteriumcontroles 4/4
De CEO UiPath is Daniel Dines, benoemd in Jan2005, heeft een ambtstermijn van 21.5 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 1.35M, bestaande uit 0.4% salaris en 99.6% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 19.73% van de aandelen van het bedrijf, ter waarde $ 1.19B. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 3.8 jaar en 4.9 jaar.
Belangrijke informatie
Daniel Dines
Algemeen directeur
US$1.3m
Totale compensatie
| Percentage CEO-salaris | 0.45% |
| Dienstverband CEO | 21.5yrs |
| Eigendom CEO | 19.7% |
| Management gemiddelde ambtstermijn | 3.8yrs |
| Gemiddelde ambtstermijn bestuur | 4.9yrs |
Recente managementupdates
Recent updates
Narratiefupdate • Jul 10
PATH: AI Automation And ARR Execution Will Drive Future Repricing
UiPath's analyst fair value estimate has been trimmed from $17.00 to about $16.29 as analysts adjust their price targets into a tighter $12 to $15 range. This reflects solid recent results, but also a preference to see stronger, more consistent ARR momentum and clearer AI driven benefits before becoming more positive.
Narratiefupdate • Jun 26
PATH: Agentic AI Adoption Will Strengthen Future ARR Visibility Despite Cautious Sentiment
UiPath's consensus narrative has shifted slightly lower as the average analyst price target edges down by about $0.50. This reflects solid Q1 results and improved profitability assumptions, offset by more cautious expectations for revenue growth and future P/E multiples, while analysts wait for clearer evidence of faster ARR growth from AI driven deals.Analyse-artikel • Jun 17
UiPath (PATH) Stock Could Be 24% Undervalued After Maestro Case Launch
UiPath (PATH) is back in focus after launching Maestro Case, an AI-native case management capability that targets complex, exception-heavy workflows, with early adopters reporting sizable efficiency gains and projected cost savings. See our latest analysis for UiPath. Despite Maestro Case and recent customer wins such as One New Zealand Limited, short term selling pressure has left UiPath’s share price down 33.75% year to date and the 5 year total shareholder return down 84.94%. This points...Analyse-artikel • Jun 11
UiPath's (NYSE:PATH) Promising Earnings May Rest On Soft Foundations
UiPath, Inc. ( NYSE:PATH ) just reported some strong earnings, and the market reacted accordingly with a healthy uplift...Seeking Alpha • Jun 10
UiPath: Overlooked Company With Visible Automation Tailwinds
Summary UiPath is delivering accelerating revenue growth and rising ARR, benefiting from the broader AI-driven business transformation. Despite a strong Q1 beat-and-raise, PATH shares remain down ~30% YTD, creating a compelling entry point. PATH's ARR nears $2 billion, outpacing full-year revenue guidance and providing strong demand visibility. With GAAP gross margins in the low 80s and a near-Rule of 40 profile, I reiterate my buy rating on PATH. Read the full article on Seeking Alpha
Nieuw narratief • May 18
AI Automation Demand And Margin Expansion Will Support Steady Performance Over Time
Catalysts About UiPath UiPath provides an automation and AI software platform that helps enterprises build, orchestrate and govern digital workflows. What are the underlying business or industry changes driving this perspective?Narratiefupdate • May 02
PATH: Agentic AI Automation Adoption Will Drive Future ARR Stability
Analysts have trimmed their average price targets on UiPath by several dollars, bringing them into a roughly $12 to $17 range. They cited strong Q4 execution and growing AI driven automation use cases, along with valuation compression across software peers and a need for clearer evidence of sustained AI monetization and net new ARR growth.Narratiefupdate • Apr 18
PATH: Agentic AI Automation And ARR Stability Will Drive Future Upside
Analysts have reduced UiPath's average price target by a few dollars to a roughly mid-teens dollar value. They cite solid Q4 execution and ARR trends, but also point to valuation compression across software peers, along with a need for clearer AI monetization and sustained net new ARR growth.Narratiefupdate • Apr 03
PATH: Agentic AI Automation And ARR Stability Will Support Future Upside
Analysts have nudged the average price target for UiPath slightly lower to around the mid teens in $ terms, trimming expectations on valuation multiples, even as they cite solid Q4 execution, steady ARR trends and growing interest in AI driven automation as key supports for the story. Analyst Commentary Recent research points to a mixed but generally balanced view on UiPath, with most firms trimming price targets while acknowledging solid Q4 execution, resilient ARR and growing interest in AI driven automation.Narratiefupdate • Mar 20
PATH: Agentic AI Automation And Healthcare Solutions Will Support Future Upside
UiPath's updated analyst fair value estimate has shifted from $15.93 to $13.81 as analysts reset price targets across the $12 to $18 range, weighing solid Q4 execution, AI driven automation traction and improving margins against valuation compression, flat to stabilizing net new ARR, and the need for clearer proof of sustained AI monetization. Analyst Commentary Recent research points to a split view on UiPath, with most firms reducing price targets but highlighting both encouraging execution in Q4 and unresolved questions around future growth and valuation.Nieuw narratief • Mar 12
AI Automation Platform Will Benefit From Long Term Cross System Workflow Complexity
Catalysts About UiPath UiPath provides an end to end automation and AI platform that helps enterprises automate complex workflows across systems, people and software. What are the underlying business or industry changes driving this perspective?Narratiefupdate • Mar 06
PATH: Healthcare AI Launch And Index Additions Will Support Future Upside
Analysts have trimmed their blended price target for UiPath by about $0.27 to reflect a slightly lower fair value estimate of $15.93, modestly higher discount rate assumptions, and only small tweaks to long term margin and P/E expectations. Analyst Commentary Bullish Takeaways Bullish analysts see scope for UiPath to reach a price target of US$18, which sits above the trimmed blended fair value estimate of US$15.93, suggesting room for upside if execution aligns with their assumptions.Narratiefupdate • Feb 19
PATH: Index Additions And Buybacks Will Support Future Automation Upside
Analysts have trimmed their UiPath fair value estimate slightly to $16.19 from $16.40, citing mixed expectations around future profitability and valuation multiples, even as revenue assumptions stay relatively steady. Analyst Commentary Street research on UiPath reflects a mix of optimism around sector conditions and caution around how that translates into the company’s valuation and execution over time.Analyse-artikel • Feb 06
Some Confidence Is Lacking In UiPath, Inc. (NYSE:PATH) As Shares Slide 30%
UiPath, Inc. ( NYSE:PATH ) shares have had a horrible month, losing 30% after a relatively good period beforehand. The...Narratiefupdate • Feb 05
PATH: AI Software Setup And Index Adds Will Support Automation Outlook
Narrative Update on UiPath UiPath’s implied analyst price target has ticked higher as recent research cites a move from $16 to $18 at one firm and from $12 to $14 at another, with analysts pointing to a generally supportive backdrop for software and ongoing interest in AI related opportunities as key drivers for the updated views. Analyst Commentary Recent research on UiPath centers on how the shares might reflect a mixed backdrop for software, AI related themes, and current valuation levels.Narratiefupdate • Jan 21
PATH: AI Software Setup And Index Adds Will Support Automation Outlook
Narrative update Analysts have nudged their fair value view for UiPath slightly higher, reflecting price target moves such as Barclays lifting its target to US$18 from US$16 and RBC Capital moving to US$14 from US$12, citing a more constructive setup for software and AI exposed names. Analyst Commentary Recent research is broadly constructive, but it also highlights that expectations around AI and software can still be a source of swings in sentiment for UiPath.Narratiefupdate • Jan 07
PATH: AI Trade Enthusiasm And Index Adds Will Shape Automation Outlook
Analysts have inched their fair value estimate for UiPath lower from $16.40 to about $16.27 per share, while still lifting some price targets, such as the move to $14 at RBC Capital. This reflects mixed views as they weigh AI related enthusiasm against updated assumptions for growth, margins and future P/E multiples.Analyse-artikel • Dec 23
UiPath Inc.'s (NYSE:PATH) 28% Price Boost Is Out Of Tune With Revenues
The UiPath Inc. ( NYSE:PATH ) share price has done very well over the last month, posting an excellent gain of 28%. The...Narratiefupdate • Dec 21
PATH: AI Partnerships Will Support Automation Gains While Competition Keeps Outlook Balanced
Analysts have modestly increased their fair value estimate for UiPath from approximately $15.93 to $16.40 per share, reflecting a slightly higher long term growth outlook supported by recent price target raises tied to AI driven product enhancements and partnerships, despite ongoing competitive pressures. Analyst Commentary Recent Street commentary reflects a cautiously constructive stance on UiPath, with modest target price increases framed by both optimism around AI driven automation and recognition of intense competitive dynamics.Narratiefupdate • Dec 07
PATH: AI Partnerships Will Drive Automation Hype Yet Leave Shares Vulnerable
UiPath's updated fair value estimate has risen to approximately $15.93 from $13.86, as analysts modestly lift price targets in response to new product launches, strategic partnerships, and expectations that the company can increasingly leverage AI trends, despite a still competitive market. Analyst Commentary Analysts remain measured on UiPath, modestly increasing price targets while keeping neutral ratings as they weigh improving product momentum against a still challenging competitive backdrop.Narratiefupdate • Nov 23
PATH: Partnerships And New AI Offerings Will Shape Automation Leadership Ahead
Analysts have modestly increased their price target for UiPath, raising it from approximately $13.71 to $13.86 per share. They cite recent product updates and ongoing developments in the AI and automation space as supportive factors for the adjustment.Narratiefupdate • Nov 08
PATH: Product Partnerships And Updates Will Shape Future Opportunities In Automation
UiPath's analyst price target has increased to $13 from $12.50, as analysts recognize ongoing product updates and partnerships but remain cautious about the company's growth prospects in a competitive market. Analyst Commentary Recent analyst updates reflect a nuanced perspective on UiPath's future, highlighting both supportive and cautious sentiments about the company's execution and long-term growth prospects.Narratiefupdate • Oct 25
Expanding Automation Partnerships And AI-Powered Agents Will Drive Business Momentum
UiPath’s analyst price target has been revised upward to $13 from $12.50, as analysts cite ongoing product innovation and new partnerships. This comes despite expectations of gradual top-line impact amid ongoing market competition.Narratiefupdate • Oct 10
Agent Builder And Agentic Orchestration Will Expand Market Opportunities
UiPath’s analyst price target has been modestly increased from $13.30 to $13.44, as analysts cite ongoing product and partnership developments. However, they also note persistent competitive pressures in the automation market.Analyse-artikel • Oct 07
What UiPath Inc.'s (NYSE:PATH) 26% Share Price Gain Is Not Telling You
UiPath Inc. ( NYSE:PATH ) shareholders would be excited to see that the share price has had a great month, posting a...Narratiefupdate • Sep 06
Agent Builder And Agentic Orchestration Will Expand Market Opportunities
UiPath’s price target has been revised down due to a sharp year-over-year decline in net new ARR and heightened long-term market uncertainty, reflecting a lowered fair value from $14.15 to $13.30. Analyst Commentary Net new annual recurring revenue rose by $30M, but this represents a 30% year-over-year decline.Analyse-artikel • Jul 23
When Should You Buy UiPath Inc. (NYSE:PATH)?
UiPath Inc. ( NYSE:PATH ), might not be a large cap stock, but it saw a significant share price rise of 23% in the past...Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Apr 30 2026 | n/a | n/a | US$327m |
| Jan 31 2026 | US$1m | US$6k | US$282m |
| Oct 31 2025 | n/a | n/a | US$230m |
| Jul 31 2025 | n/a | n/a | US$20m |
| Apr 30 2025 | n/a | n/a | -US$68m |
| Jan 31 2025 | US$1m | US$6k | -US$74m |
| Oct 31 2024 | n/a | n/a | -US$92m |
| Jul 31 2024 | n/a | n/a | -US$112m |
| Apr 30 2024 | n/a | n/a | -US$87m |
| Jan 31 2024 | US$726k | US$6k | -US$90m |
| Oct 31 2023 | n/a | n/a | -US$151m |
| Jul 31 2023 | n/a | n/a | -US$178m |
| Apr 30 2023 | n/a | n/a | -US$238m |
| Jan 31 2023 | US$772k | US$6k | -US$328m |
| Oct 31 2022 | n/a | n/a | -US$364m |
| Jul 31 2022 | n/a | n/a | -US$429m |
| Apr 30 2022 | n/a | n/a | -US$408m |
| Jan 31 2022 | US$670k | US$6k | -US$526m |
| Oct 31 2021 | n/a | n/a | -US$436m |
| Jul 31 2021 | n/a | n/a | -US$384m |
| Apr 30 2021 | n/a | n/a | -US$284m |
| Jan 31 2021 | US$216k | US$106k | -US$92m |
Compensatie versus markt: De totale vergoeding ($USD 1.35M ) Daniel } ligt onder het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 8.33M ).
Compensatie versus inkomsten: De vergoeding van Daniel is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.
CEO
Daniel Dines (54 yo)
21.5yrs
Tenure
US$1,347,430
Compensatie
Mr. Daniel Solomon Dines is the Co-Founder & General Partner of Crew Capital. He is an entrepreneur, engineer and investor. He co-founded UiPath Inc in 2005 and was its Chief Innovation Officer from Februa...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Co-Founder | 21.5yrs | US$1.35m | 19.73% $ 1.2b | |
| CFO & COO | 6.7yrs | US$7.43m | 0.052% $ 3.2m | |
| General Counsel | 7.3yrs | US$3.98m | 0.085% $ 5.1m | |
| Deputy CFO & Chief Accounting Officer | no data | geen gegevens | 0.011% $ 649.9k | |
| Chief Product & Technology Officer | 2.2yrs | geen gegevens | 0.050% $ 3.0m | |
| Senior Director of Investor Relations | no data | geen gegevens | geen gegevens | |
| Chief Marketing Officer | less than a year | geen gegevens | geen gegevens | |
| Chief People Officer | 2.5yrs | geen gegevens | geen gegevens | |
| Chief Culture Officer | 5.3yrs | geen gegevens | geen gegevens | |
| Chief Strategy Officer | no data | geen gegevens | geen gegevens | |
| Senior VP & MD of EMEA | 3.8yrs | geen gegevens | geen gegevens | |
| Senior Vice President of Services & Customer Success | 2.5yrs | geen gegevens | geen gegevens |
3.8yrs
Gemiddelde duur
51yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van PATH wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.8 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Co-Founder | 20.8yrs | US$1.35m | 19.73% $ 1.2b | |
| Independent Director | 5.3yrs | US$265.14k | 0.026% $ 1.6m | |
| Chairman of Artificial Intelligence Advisory Board | 4.7yrs | geen gegevens | geen gegevens | |
| Independent Lead Director | 8.3yrs | US$265.14k | 0.16% $ 9.9m | |
| Member of Public Sector Advisory Board | 4.9yrs | geen gegevens | geen gegevens | |
| Independent Director | 6.4yrs | US$250.14k | 0.61% $ 36.9m | |
| Independent Director | 5.8yrs | US$260.14k | 0.034% $ 2.0m | |
| Member of Public Sector Advisory Board | 4.9yrs | geen gegevens | geen gegevens | |
| Member of Public Sector Advisory Board | 4.9yrs | geen gegevens | geen gegevens | |
| Member of Public Sector Advisory Board | 4.9yrs | geen gegevens | geen gegevens | |
| Member of Public Sector Advisory Board | 4.9yrs | geen gegevens | geen gegevens | |
| Member of Public Sector Advisory Board | 4.9yrs | geen gegevens | geen gegevens |
4.9yrs
Gemiddelde duur
56yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van PATH wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.9 jaar).
Bedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/07/13 11:45 |
| Aandelenkoers aan het einde van de dag | 2026/07/10 00:00 |
| Inkomsten | 2026/04/30 |
| Jaarlijkse inkomsten | 2026/01/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysamodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina, we hebben ook handleidingen over hoe u onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
UiPath, Inc. wordt gevolgd door 30 analisten. 20 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| Raimo Lenschow | Barclays |
| William Kingsley Crane | Berenberg |
| Keith Bachman | BMO Capital Markets Equity Research |